A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Preliminary Anti-tumor Activity of SYS6005 in Patients With Advanced Malignant Tumor
Latest Information Update: 22 May 2025
At a glance
- Drugs SYS 6005 (Primary)
- Indications Adrenal cancer; Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gynaecological cancer; Hodgkin's disease; Lung cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Skin cancer; Solid tumours; Testicular cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CSPC Pharmaceutical Group
Most Recent Events
- 09 May 2025 Status changed from not yet recruiting to recruiting.
- 15 Apr 2025 According to a Radiance Biopharma media release, company announced that the first patient in China has been dosed in this Phase 1 clinical trial.
- 01 Apr 2025 According to a Radiance Biopharma media release, company announced that the IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of RB-164 in patients with ROR-1 positive hematologic and solid cancers in the United States of America.